A WEP Clinical White Paper
With Every Patient
In Recognition of International Childhood Cancer Day – February 15
Executive Summary
Scientific innovation in pediatric oncology has accelerated, yet clinical trial participation among children with cancer remains constrained by factors unrelated to therapeutic promise. Families face logistical, financial, and emotional burdens that make trial participation difficult to sustain, while pediatric oncology sites operate under increasing pressure from complex protocols and limited resources.
This white paper explores why traditional, adult-centric trial designs disproportionately burden pediatric patients and their families, and how family-centric execution models can improve enrollment, retention, data quality, and global access without compromising scientific rigor.
Designing trials families can say yes to is not a matter of convenience; it is an operational necessity. Programs that account for family realities perform better, scale more effectively, and reach patients who would otherwise be excluded from research.
The Pediatric Oncology Reality: High Need, High Friction
Childhood cancer remains a leading cause of disease-related mortality among children globally. While therapeutic pipelines continue to expand, pediatric trials face persistent operational friction driven by:
- Small and geographically dispersed patient populations
- Complex ethical and consent considerations
- Highly specialized care settings
- Limited site staffing and infrastructure
Despite these challenges, many pediatric trials continue to rely on execution models designed for adult oncology, which unintentionally increase burden on families and sites.
The Burden Families Carry Before a Trial Even Begins
For families, participation decisions are shaped less by scientific merit and more by feasibility.
Common Sources of Family Burden:
- Repeated long-distance travel to specialty sites
- Rigid visit schedules that disrupt schooling and caregiving
- Multi-hour clinic visits with numerous assessments
- Caregiver work interruption and financial strain
- Emotional fatigue from frequent hospital exposure
When burdens accumulate, families decline participation or withdraw early. This introduces delays, protocol deviations, and data gaps that affect trial integrity.
Why Enrollment Challenges Are Often Design Problems
Low enrollment and retention in pediatric trials are frequently attributed to rarity or lack of awareness. In practice, they are often symptoms of misaligned trial design.
Families ask practical questions:
- Can we realistically manage this alongside treatment?
- What happens to our other children?
- How much time will this require every week?
- Will this overwhelm our child?
Trials that fail to anticipate these realities inadvertently limit access, even when clinical rationale is strong.
Re-Engineering Trials Around the Family Unit
Family-centric trial design does not reduce rigor; it increases feasibility.
Core Design Principles
- Visit Compression
- Combine assessments into fewer visits
- Eliminate duplicative procedures
- Align trial visits with standard-of-care appointments
Outcome: Reduced travel frequency and improved protocol adherence.
- Scheduling Flexibility
- Defined visit windows rather than fixed dates
- Accommodation for school calendars and caregiver schedules
- Selective evening or weekend options where feasible
Outcome: Higher enrollment acceptance and fewer missed visits.
- Hybrid and Decentralized Touchpoints
- Home health services for routine assessments
- Telemedicine for follow-up visits
- Remote capture of patient-reported outcomes
Outcome: Expanded geographic reach and reduced site congestion.
- Child-Appropriate Endpoint Selection
- Focus on clinically meaningful endpoints
- Minimize invasive or low-value assessments
- Account for age-specific tolerability and experience
Outcome: Improved data quality and participant retention.
Supporting the Entire Family Ecosystem
In pediatric oncology, the patient does not participate alone. Trials must account for caregivers, siblings, and household dynamics.
Operational Supports That Enable Participation:
- Coordinated travel and lodging logistics
- Clear and timely reimbursement processes
- Centralized scheduling assistance
- A single, consistent point of contact for families
These elements are often treated as ancillary services, yet they are foundational to sustainable participation.
Recognizing Site Burden and Family Burden Are Interconnected
Pediatric oncology sites operate with limited staffing while managing increasing protocol complexity. When sites are overextended, families experience delays, rescheduling, and fragmented communication.
Execution Models That Support Sites and Families:
- Dedicated pediatric study coordination support
- Simplified monitoring strategies with remote oversight
- Lean governance and clear escalation pathways
- Reduced administrative load on clinical staff
Supporting sites directly improves the family experience and strengthens trial performance.
Expanding Access Through Family-Centric Global Models
Most children with cancer live outside major academic centers. Traditional site-heavy models limit access to a narrow subset of patients.
Family-centric global execution enables:
- Regionalized trial delivery with centralized oversight
- Integration of community and regional hospitals
- Remote monitoring paired with local care delivery
- Culturally appropriate consent and education approaches
Reducing burden is inseparable from advancing equity in pediatric research.
Rethinking Success Metrics in Pediatric Trials
Traditional metrics such as enrollment speed and database lock provide an incomplete picture in pediatric programs.
Family-centric trials should also measure:
- Enrollment acceptance rates
- Early withdrawal drivers
- Protocol deviation root causes
- Family and site experience feedback
- Site workload sustainability
These indicators serve as early signals of trial resilience and scalability.
International Childhood Cancer Day: From Awareness to Action
International Childhood Cancer Day is an opportunity to move beyond recognition toward meaningful change.
Progress requires:
- Earlier operational input during protocol development
- Willingness to challenge adult-centric assumptions
- Investment in flexible, fit-for-purpose infrastructure
- True partnership with families and sites
Childhood cancer research does not need bigger systems. It needs smarter, more compassionate execution.
Conclusion
International Childhood Cancer Day is an opportunity to move beyond recognition toward meaningful change.
Progress requires:
- Earlier operational input during protocol development
- Willingness to challenge adult-centric assumptions
- Investment in flexible, fit-for-purpose infrastructure
- True partnership with families and sites
Childhood cancer research does not need bigger systems. It needs smarter, more compassionate execution.
About WEP Clinical
WEP Clinical is a global clinical development partner specializing in oncology and rare disease programs. We support emerging and mid-size biopharma companies with adaptive, patient-centered solutions that enable early-phase innovation and sustainable growth – always With Every Patient.
If you would like to connect to discuss how we can support your team, please reach out to us – [email protected]
